| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10018499 | HBV | ENSG00000136872.21 | protein_coding | ALDOB | No | No | 229 | P05062 |
| TVIS10013129 | HBV | ENSG00000136872.21 | protein_coding | ALDOB | No | No | 229 | P05062 |
| TVIS10018498 | HBV | ENSG00000136872.21 | protein_coding | ALDOB | No | No | 229 | P05062 |
| TVIS10050690 | HBV | ENSG00000136872.21 | protein_coding | ALDOB | No | No | 229 | P05062 |
| TVIS10047438 | HBV | ENSG00000136872.21 | protein_coding | ALDOB | No | No | 229 | P05062 |
| TVIS10047439 | HBV | ENSG00000136872.21 | protein_coding | ALDOB | No | No | 229 | P05062 |
| TVIS10046441 | HBV | ENSG00000136872.21 | protein_coding | ALDOB | No | No | 229 | P05062 |
| TVIS10061038 | HBV | ENSG00000136872.21 | protein_coding | ALDOB | No | No | 229 | P05062 |
| TVIS10061037 | HBV | ENSG00000136872.21 | protein_coding | ALDOB | No | No | 229 | P05062 |
| TVIS10061036 | HBV | ENSG00000136872.21 | protein_coding | ALDOB | No | No | 229 | P05062 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | ALDOB |
|---|---|
| DrugBank ID | DB02515 |
| Drug Name | sn-glycerol 3-phosphate |
| Target ID | BE0004565 |
| UniProt ID | P05062 |
| Regulation Type | |
| PubMed IDs | 17139284; 17016423; 10592235 |
| Citations | Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. |
| Groups | Experimental |
| Direct Classification | Glycerophosphates |
| SMILES | OC[C@@H](O)COP(O)(O)=O |
| Pathways | De Novo Triacylglycerol Biosynthesis TG(16:0/16:1(9Z)/18:2(9Z,12Z)); De Novo Triacylglycerol Biosynthesis TG(16:0/18:2(9Z,12Z)/18:2(9Z,12Z)); De Novo Triacylglycerol Biosynthesis TG(16:0/18:0/20:4(5Z,8Z,11Z,14Z)); De Novo Triacylglycerol Biosynthesis TG(16:0/16:1(9Z)/18:1(9Z)); De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/20:0/20:4(5Z,8Z,11Z,14Z)); De Novo Triacylglycerol Biosynthesis TG(20:0/20:0/20:1(11Z)); De Novo Triacylglycerol Biosynthesis TG(18:0/20:1(11Z)/20:1(11Z)); Glycerol Phosphate Shuttle; De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/20:0/20:1(11Z)); De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/18:1(9Z)/18:2(9Z,12Z)); De Novo Triacylglycerol Biosynthesis TG(16:0/20:0/20:0); De Novo Triacylglycerol Biosynthesis TG(18:0/18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z)); De Novo Triacylglycerol Biosynthesis TG(16:0/16:0/16:0); De Novo Triacylglycerol Biosynthesis TG(16:0/20:0/20:4(5Z,8Z,11Z,14Z)); De Novo Triacylglycerol Biosynthesis TG(20:0/20:1(11Z)/20:4(5Z,8Z,11Z,14Z)); De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/20:0/20:0); De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/20:1(11Z)); De Novo Triacylglycerol Biosynthesis TG(16:0/18:0/18:1(9Z)); De Novo Triacylglycerol Biosynthesis TG(16:0/18:1(9Z)/20:0); De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/20:4(5Z,8Z,11Z,14Z)); De Novo Triacylglycerol Biosynthesis TG(18:0/18:0/18:0); De Novo Triacylglycerol Biosynthesis TG(18:0/18:0/20:0); De Novo Triacylglycerol Biosynthesis TG(16:0/18:0/18:0); De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/18:2(9Z,12Z)); De Novo Triacylglycerol Biosynthesis TG(20:0/20:1(11Z)/20:1(11Z)); De Novo Triacylglycerol Biosynthesis TG(16:0/18:0/20:0); De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/18:1(9Z)/18:1(9Z)); De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/20:1(11Z)/20:1(11Z)); Glycerol Kinase Deficiency; De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/18:1(9Z)/20:1(11Z)) |
| PharmGKB | |
| ChEMBL | CHEMBL1232920 |
